Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines.
Effendi WI, Nagano T, Tachihara M, Umezawa K, Kiriu T, Dokuni R, Katsurada M, Yamamoto M, Kobayashi K, Nishimura Y. Effendi WI, et al. Among authors: nagano t. Cancer Manag Res. 2019 Apr 29;11:3669-3679. doi: 10.2147/CMAR.S193789. eCollection 2019. Cancer Manag Res. 2019. PMID: 31118789 Free PMC article.
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Tachihara M, Kiriu T, Hata A, Hatakeyama Y, Nakata K, Nagano T, Yamamoto M, Kobayashi K, Ohnishi H, Katakami N, Nishimura Y. Tachihara M, et al. Among authors: nagano t. Cancer Manag Res. 2019 Jul 29;11:7135-7140. doi: 10.2147/CMAR.S208224. eCollection 2019. Cancer Manag Res. 2019. PMID: 31534366 Free PMC article.
Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non-small cell lung cancer.
Tachihara M, Dokuni R, Okuno K, Tokunaga S, Nakata K, Katsurada N, Yamamoto M, Nagano T, Kobayashi K, Tanaka Y, Funada Y, Maniwa Y, Nishimura Y. Tachihara M, et al. Among authors: nagano t. Thorac Cancer. 2020 Sep;11(9):2536-2541. doi: 10.1111/1759-7714.13567. Epub 2020 Jul 30. Thorac Cancer. 2020. PMID: 32729237 Free PMC article. Clinical Trial.
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F. Zhang T, et al. Among authors: nagano t. Transl Lung Cancer Res. 2021 Apr;10(4):1857-1872. doi: 10.21037/tlcr-21-303. Transl Lung Cancer Res. 2021. PMID: 34012798 Free PMC article.
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Zhao Y, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Chen W, Luo Y, Wu L, Wang X, Nan K, Jin F, Dong J, Li B, Yamaguchi F, Breadner D, Nagano T, Tanaka F, Husain H, Li K, Han B. Zhao Y, et al. Among authors: nagano t. Transl Lung Cancer Res. 2022 May;11(5):776-785. doi: 10.21037/tlcr-22-320. Transl Lung Cancer Res. 2022. PMID: 35693290 Free PMC article.
Re-challenge chemotherapy for relapsed non-small-cell lung cancer.
Nagano T, Kim YH, Goto K, Kubota K, Ohmatsu H, Niho S, Yoh K, Naito Y, Saijo N, Nishiwaki Y. Nagano T, et al. Lung Cancer. 2010 Sep;69(3):315-8. doi: 10.1016/j.lungcan.2009.11.016. Epub 2010 Jan 13. Lung Cancer. 2010. PMID: 20071052
1,358 results